Emergency icon Important Updates

Richard Rothman, MD

Richard Rothman, MD
  • No ratings
  • 0 Patient Satisfaction Ratings
  • 0 Patient Comments
Title Vice-Chief of the Integrated Hospital Care Institute, Florida Region
Department Hospital Medicine
Primary Location Cleveland Clinic Florida, Indian River Hospital
Type of Doctor Both Adults and Children & Adolescents
Languages English
Surgeon No
Locations Specialties & Treatments

Treatment & Services

  • Adult Medicine
  • Care At Home
  • Hospital Based Care
  • Inpatient Care
  • Perioperative Care
  • Post-Acute Care
View all 6 Treatment & Services +

Specialty in Diseases & Conditions

  • Perioperative Medicine
View all 1 Specialties +


Is Cleveland Clinic Florida Part of Your Insurance?

Review a list of accepted insurance plans for our Florida locations or learn more about purchasing a contracted managed care plan.

View All Plans

About Richard Rothman, MD

As Regional Chief Medical Operations Officer for Cleveland Clinic Florida and the Florida Market leader of the Integrated Hospital Care Institute for Cleveland Clinic, Dr. Richard Rothman is one of the founders of Cleveland Clinic Hospital Care at Home. He graduated from St. George’s University School of Medicine in 2009 and did a post-doctoral research fellowship at the Massachusetts General Hospital in Boston, Ma. He completed both his internship and residency at the Lahey Clinic, also in Massachusetts. He has his diplomate in Internal Medicine from the American Board of Internal Medicine and is an active member of the American College of Physicians and Society of Hospital Medicine.

Citation Bibliography: 

  1. Rothman RD, Delaney CP, Heaton BM, Hohman JA. Early experience and lessons following the implementation of a Hospital-at-Home program. Journal of hospital medicine. 2024. doi: 10.1002/jhm.13293
  2. Rothman RD and Delaney, CP. Hospital Care at Home: How Cleveland Clinic reimagined acute hospital care delivery. Becker's Hospital Review: Leadership and Management. 2024. 
  3. Rothman RD, Peter DJ, Harte BJ. Improving Healthcare Value: Managing Length of Stay and Improving the Hospital Medicine Value Proposition. Journal of hospital medicine. 2021;16:620-622. doi: 10.12788/jhm.3662
  4. Rothman RD, Whinney CM, Pappas MA, Zoller DM, Rosencrance JG, Peter DJ. The relationship between the follow-up to discharge ratio and length of stay. Am J Manag Care. 2020;26:396-399. doi: 10.37765/ajmc.2020.88490
  5. McCullough SA, Shimada YJ, Baggish AL, Lowry PA, O’Callaghan C, Rothman RD, Vlahakes GJ, Fifer MA. Abstract 12390: Right Heart Failure Predicts Higher Mortality in Patients With Hypertrophic Cardiomyopathy. Circulation. 2014;130:A12390-A12390.
  6. Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, Abbara S, Ghoshhajra BB, Rothman RD, Ho CY, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart failure. 2013;1:480-487. doi: 10.1016/j.jchf.2013.09.001
  7. Iqtidar AF, Jeon C, Rothman R, Snead R, Pyne CT. Reduction in operator radiation exposure during transradial catheterization and intervention using a simple lead drape. American Heart Journal. 2013;165:293-298. doi: 10.1016/j.ahj.2012.10.002
  8. Shkolnik LE, Shin RD, Brabeck DM, Rothman RD. Symptomatic gastric sarcoidosis in a patient with pulmonary sarcoidosis in remission. BMJ case reports. 2012;2012. doi: 10.1136/bcr-2012-006559
  9. Rothman RD, Baggish AL, O'Callaghan C, Lowry PA, Bhatt AB, MacRae CA, Yannekis G, Sanborn DM, Mela T, Yeh RW, et al. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. The American journal of cardiology. 2012;110:1169-1174. doi: 10.1016/j.amjcard.2012.05.056
  10. Rothman RD, Weiner RB, Pope H, Kanayama G, Hutter AM, Jr., Fifer MA, Dec GW, Jr., Baggish AL. Anabolic androgenic steroid induced myocardial toxicity: an evolving problem in an ageing population. BMJ case reports. 2011;2011. doi: 10.1136/bcr.05.2011.4280
  11. Rothman RD, Safiia MA, Lowry PA, Mela T, Abbara S, O’Callaghan C, Mark EJ, Vlahakes GJ, Fifer MA. Risk stratification for sudden cardiac death after septal myectomy. Journal of Cardiology Cases. 2011;3:e65-e67. doi: 10.1016/j.jccase.2010.12.002
  12. Rothman RD, Safiia MA, Lowry PA, Mela T, Abbara S, O'Callaghan C, Mark EJ, Vlahakes GJ, Fifer MA. Risk stratification for sudden cardiac death after septal myectomy. J Cardiol Cases. 2011;3:e65-e67. doi: 10.1016/j.jccase.2010.12.002
  13. Rothman RD, Delaney CP, Heaton BM, Hohman JA. Early experience and lessons following the implementation of a Hospital-at-Home program. Journal of hospital medicine.n/a. doi: https://doi.org/10.1002/jhm.13293
Education & Professional Highlights

Education & Professional Highlights


Education & Fellowships

Residency - Lahey Clinic Medical Center (Massachusetts)
Internal Medicine
Burlington, MA United States

Internship - Lahey Clinic Medical Center (Massachusetts)
Internal Medicine
Burlington, MA United States

Medical Education - St Georges School of Medicine (Grenada)
Bay Shore, NY Grenada


  • Internal Medicine
Research & Publications

Research & Publications

See publications for Richard Rothman, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 3/23/2024, Dr. Rothman has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Rothman receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

  • Medically Home Group, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Back to Top